View Older Stories View More Recent Stories

Nov 7, 2018 05:06PM New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
Nov 7, 2018 05:00PM New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial
Nov 6, 2018 01:01AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Nov 1, 2018 09:22AM New Data at ASH Showcase Bioverativ’s Commitment to Transforming Care for People with Hemophilia and Other Rare Blood Disorders
Oct 23, 2018 08:05AM Santander Bank Launches "In Someone Else's Shoes" to Highlight the Importance of Respect
Oct 22, 2018 10:32PM Mexico's next president vows security for banks in Santander meeting
Oct 19, 2018 05:59PM Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:55PM FDA approves asthsma indication for Dupixent® (dupilumab)
Oct 19, 2018 08:02AM European politicians call for clampdown on tax trade trick
Oct 16, 2018 08:00AM Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Oct 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Sep 28, 2018 04:41PM Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 17, 2018 07:30AM National Meningitis Association Urges Parents to Get Their Teens The 16 Vaccine to Help Protect Against Meningococcal Meningitis
Sep 15, 2018 02:04AM Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)
Sep 12, 2018 08:00AM FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Sep 12, 2018 01:01AM FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Jun 11, 2018 07:00AM Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccines for Infectious Diseases using Novel mRNA Technology
Jun 4, 2018 02:16PM Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:15PM New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:15PM New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
May 21, 2018 02:16PM Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 21, 2018 02:15PM New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 16, 2018 08:00AM Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 1, 2018 07:06AM Sanofi (SNY) and Regeneron (REGN) to Lower Net Price of Praluent; Praluent will become Exclusive PCSK9 inhibitor Therapy on Express Scripts (ESRX) National Formulary
May 1, 2018 07:00AM Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients
Apr 30, 2018 01:02AM Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Apr 30, 2018 01:00AM FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Mar 10, 2018 09:03AM Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
Mar 10, 2018 09:02AM Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
Mar 10, 2018 09:01AM Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Mar 10, 2018 09:00AM Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
Mar 8, 2018 06:00AM Santander Consumer USA And AutoGravity Work To Transform The Car-Buying And Financing Journey
Mar 2, 2018 01:01AM Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
Feb 8, 2018 05:56AM Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.
Jan 22, 2018 01:10AM Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 22, 2018 01:04AM Sanofi to Acquire Bioverativ for $11.6 Billion
Jan 8, 2018 07:01AM Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
Jan 7, 2018 03:01PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Dec 18, 2017 07:01AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
Dec 15, 2017 07:03AM Sanofi (SNY) and Alnylam (ALNY) Announce FDA Lifted Clinical hold on Fitusiran
Dec 15, 2017 07:01AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 13, 2017 01:02AM Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
Nov 16, 2017 08:00AM American Express Introduces Blockchain-Enabled Cross-Border Business-to-Business Payments
Nov 2, 2017 10:46AM Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
Oct 31, 2017 07:14AM Sanofi (SNY) Says Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma
Oct 31, 2017 06:59AM Sanofi : Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma
Oct 16, 2017 08:02AM Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Oct 16, 2017 08:00AM Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
View More Recent Stories View Older Stories